R&D
Partner Content
4th mRNA-Based Therapeutics Summit
Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to …
19736 items found
R&D
Dark factories for a bright future
Much like medicine itself, drug manufacturing has evolved rapidly …
News
Cannabinoids show promise in acute migraine clinical trial
Inhaled cannabinoids have been shown to perform better than placebo …
News
Bayer pays $310m for Euro rights to ATTR therapy acoramidis
Bayer has shored up its near-term pipeline by acquiring European …
News
EMA starts twin reviews of AZ, Daiichi’s Dato-DXd
The clock has started ticking in the EU on two marketing applications …
News
RNA therapy firm Avidity files $400m placement
Avidity Biosciences has filed a private placement worth around $400 …
News
Judge knocks back AstraZeneca’s IRA challenge
AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation …
R&D
Deep Dive: Research and Development 2024
In this edition of Deep Dive, delve into the revolutionary world of …
R&D
This week in clinical trials: 5th Feb to 9th Feb 2024
In this clinical trial round-up, we look at life sciences research …
News
4SC files maintenance CTCL therapy Kinselby in EU
German biotech 4SC has filed its oral HDAC inhibitor Kinselby with …
News
MHRA okays first drug under new mutual recognition scheme
A new formulation of Amgen’s cancer treatment Xgeva is the first to …
News
Pfizer’s new cancer unit sees eight new blockbusters by 2030
Fresh from the $43 billion acquisition of antibody-drug conjugate …
News
Astellas pulls geographic atrophy drug filing in the EU
Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.
Sales & Marketing
Enabling site success: Key insights to reducing burden and i...
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Digital
Access to genomic surveillance: Open science and public heal...
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Less than three weeks away: Join Global Experts at Transderm...
11-12 November 2024 in London, UK
R&D
Partner Content
4th mRNA Analytical Development & Quality Control Summit | F...
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
